Overview

Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy

Status:
Enrolling by invitation
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
An Open-Label Study to Evaluate Switching from a Regimen of Elvitegravir/Tenofovir alafenamide/Emtricitabine/Cobicistat and Darunavir, to a Fixed-Dose Combination of Bictegravir/Tenofovir alafenamide/Emtricitabine in Virologically Suppressed HIV-1 Subjects who are known to have a I84 V/I Mutation
Phase:
Phase 4
Details
Lead Sponsor:
Southampton Healthcare, Inc.